Glaxo Lotronex Formulary Kit Faulted For Implied Claims Beyond Studies
Executive Summary
Glaxo Wellcome Lotronex marketing materials "contain unsubstantiated Health-Related Quality of Life, productivity and economic claims" not adequately supported by clinical studies, FDA charged in an April 28 letter from the agency's Division of Drug Marketing, Advertising & Communications.
You may also be interested in...
Zelmac Cost Analysis Data Could Define Use - Committee Member
Maintenance studies for Novartis' Zelmac should include a cost analysis component, FDA Gastrointestinal Drugs Advisory Committee member Michael Wolfe, MD, said June 26.
Zelmac Cost Analysis Data Could Define Use - Committee Member
Maintenance studies for Novartis' Zelmac should include a cost analysis component, FDA Gastrointestinal Drugs Advisory Committee member Michael Wolfe, MD, said June 26.
Glaxo Lotronex Studies May Expand Market To Men, Teens, Pediatrics
Glaxo will try to expand the Lotronex (alosetron) market to men, adolescents and children, following the Feb. 9 approval of the irritable bowel syndrome treatment for use in women whose predominant IBS symptom is diarrhea.